Operational StrategyImunon's cost-effective approach, including in-house manufacturing and competitive pricing, has allowed it to beat internal cost projections for the trial.
Regulatory AdvantageIMNN-001 has orphan status in the US and EU, providing regulatory benefits and market exclusivity.
Therapy EfficacyIMNN-001 therapy led to consistent and clinically meaningful improvements in key endpoints across treatment groups, including a 13-month increase in overall survival and a 3-month increase in progression-free survival compared to standard care.